MGD 014
Alternative Names: MGD014Latest Information Update: 28 Nov 2024
At a glance
- Originator MacroGenics
- Class Antiretrovirals; Bispecific antibodies; Proteins
- Mechanism of Action CD3 antigen inhibitors; Viral RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV-1 infections
- No development reported HIV infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in HIV-infections(Treatment-experienced) in USA (Parenteral, Infusion)
- 29 May 2024 MacroGenics completes a phase I trial in HIV-1 infections (Combination therapy, treatment experienced) in the US (Parenteral) (NCT05261191)
- 24 Aug 2022 Phase-I clinical trials in HIV-1 infections (Treatment-experienced, Combination therapy) in USA (Parenteral) (NCT05261191)